Moreover, we also find two potential dysregulated mechanisms of UBE2C in HCC, including hypomethylated promoter of UBE2C and loss of inhibition of hsa-miR-193b-3p (Figure 8). This evidence concerns the gene UBE2C and hepatocellular carcinoma.